Q2 saw strong earnings growth with net income up 20% and premium revenue up 7% year-over-year. Guidance for 2026 was raised, with EPS growth expected at 8.5% and robust segment performance, especially in health. Share repurchases and AI-driven efficiency remain key priorities.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.